Nanomedicine

About: Nanomedicine is a research topic. Over the lifetime, 4287 publications have been published within this topic receiving 200647 citations.

Fluorescent Nanorods and Nanospheres for Real-Time In Vivo Probing of Nanoparticle Shape-Dependent Tumor Penetration

Abstract: Nanomedicine has offered new hope for cancer treatment.[1] Nanotherapeutics exhibit many advantages over small-molecule chemotherapeutics, including diminished systemic toxicity and improved circulation times. Unfortunately, non-uniformly leaky vasculature[2] and a dense interstitial structure[3] hinder their effective delivery to tumors.[4] These physiological abnormalities make transvascular transport—movement from vessels to the interstitium—and interstitial transport—movement through the interstitium to target cells—heterogeneous.[4a] Hence the tumor microenvironment limits the uniform penetration of nanotherapeutics by slowing or halting their transport through hydrodynamic and steric hindrance.[2a,3a,5] Overcoming these physiological barriers in tumors is an outstanding challenge for nanomedicine.

Nanotheranostics and image-guided drug delivery: current concepts and future directions.

Abstract: Nanomedicine formulations aim to improve the biodistribution and the target site accumulation of systemically applied (chemo-) therapeutics. Various different passively and actively targeted nanomedicines have been evaluated over the years, based e.g. on liposomes, polymers, micelles and antibodies, and a significant amount of (pre-) clinical evidence has been obtained showing that these 5−200 nm sized carrier materials are able to improve the therapeutic index of low-molecular-weight drugs. Besides for therapeutic purposes, however, nanomedicine formulations have also been more and more used for imaging applications, as well as, in recent years, for theranostic approaches, i.e. for systems and strategies in which disease diagnosis and therapy are combined. Potential applications of theranostic nanomedicine formulations range from the noninvasive assessment of the biodistribution and the target site accumulation of low-molecular-weight drugs, and the visualization of drug distribution and drug release at ...

Nanotoxicity: An Interplay of Oxidative Stress, Inflammation and Cell Death.

Abstract: Nanoparticles are emerging as a useful tool for a wide variety of biomedical, consumer and instrumental applications that include drug delivery systems, biosensors and environmental sensors. In particular, nanoparticles have been shown to offer greater specificity with enhanced bioavailability and less detrimental side effects as compared to the existing conventional therapies in nanomedicine. Hence, bionanotechnology has been receiving immense attention in recent years. However, despite the extensive use of nanoparticles today, there is still a limited understanding of nanoparticle-mediated toxicity. Both in vivo and in vitro studies have shown that nanoparticles are closely associated with toxicity by increasing intracellular reactive oxygen species (ROS) levels and/or the levels of pro-inflammatory mediators. The homeostatic redox state of the host becomes disrupted upon ROS induction by nanoparticles. Nanoparticles are also known to up-regulate the transcription of various pro-inflammatory genes, including tumor necrosis factor-α and IL (interleukins)-1, IL-6 and IL-8, by activating nuclear factor-kappa B (NF-κB) signaling. These sequential molecular and cellular events are known to cause oxidative stress, followed by severe cellular genotoxicity and then programmed cell death. However, the exact molecular mechanisms underlying nanotoxicity are not fully understood. This lack of knowledge is a significant impediment in the use of nanoparticles in vivo. In this review, we will provide an assessment of signaling pathways that are involved in the nanoparticle- induced oxidative stress and propose possible strategies to circumvent nanotoxicity.